Randomized, Double-Blind, Placebo-Controlled Study of Sitaxsentan to Improve Impaired Exercise Tolerance in Patients With Heart Failure and a Preserved Ejection Fraction

Study Questions:

What is the efficacy and safety of the selective endothelin type A (ETA) receptor blocker sitaxsentan in diastolic heart failure (DHF)?